logo

KREBSBIO vs SPARC: Stock Comparison

KREBS BIOCHEMICALS & IND vs SUN PHARMA ADV.RES.CO.LTDUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

SUN PHARMA ADV.RES.CO.LTD is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows a lower P/E, while SUN PHARMA ADV.RES.CO.LTD shows faster revenue growth, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 2; SPARC leads 5 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOSPARC

Valuation lens

What price are you paying?

Market CapContext only
₹125 Cr
₹5,634 Cr
P/E RatioKREBSBIO has the lower reading
0x ✓
3.56x
P/B RatioKREBSBIO has the lower reading
0x ✓
4.21x
EPSSPARC has the higher reading
₹-1.15
₹-0.64 ✓
Book ValueContext only
—
₹41.26
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SPARC is the larger company
₹5,634 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 3.56x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 4.21x
EPS
SPARC has higher earnings per share
₹-0.64 vs ₹-1.15
Revenue Growth (TTM YoY)
SPARC has faster revenue growth
6,716.8% vs 11.6%
ROCE
SPARC has a higher ROCE
83.81% vs -15.89%
Net Margin
SPARC has a higher net margin
82.65% vs -71.35%
Operating Margin
SPARC has a higher operating margin
84.46% vs -41.49%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOSPARC
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOSPARC
Live Price₹57.48₹173.09
Day Change2.53%-3.45%
Volume3,5706.64 L
52-Week High₹76.85₹289
52-Week Low₹38.33₹108
Distance from 52W High-25.2%-40.11%

Valuation

MetricKREBSBIOSPARC
Market Cap₹125 Cr₹5,634 Cr
P/E Ratio0x3.56x
P/B Ratio0x4.21x
EPS₹-1.15₹-0.64
Book Value—₹41.26
Dividend Yield0%0%

Growth

MetricKREBSBIOSPARC
Revenue Growth (TTM YoY)11.6%6,716.8%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKREBSBIOSPARC
ROE—116.01%
ROCE-15.89%83.81%
Net Margin-71.35%82.65%
Operating Margin-41.49%84.46%
Debt to Equity—0.42x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKREBSBIOSPARC
Promoter Holding72.74%65.67%
FII Holding0.5%3.75%▼ 0.15 pp
DII Holding0%0.11%▲ 0.02 pp
Public Holding26.76%30.48%▲ 0.15 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and SUN PHARMA ADV.RES.CO.LTD.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.